Deal to allow tech companies to trial products in NHS test beds

Companies involved in the Techscaler programme are being offered access to NHS regional test beds.
Entrepreneurs will work alongside clinicians (Lynne Cameron/PA)
PA Wire
Neil Pooran6 April 2023

Tech companies will be able to trial health products in clinical settings through a new partnership announced by the Scottish Government.

Companies involved in the Techscaler programme are being offered access to NHS regional test beds, which will let entrepreneurs work alongside clinicians and have access to patients.

The Government also says companies will have access to anonymised patient data to test products and ideas.

Wellbeing Economy Secretary Neil Gray announced the move during a visit to Bioliberty in Edinburgh.

Based at the National Robotarium, it uses robotics to provide rehabilitation and assistance for stroke survivors.

Mr Gray told the PA news agency that any personal data would be handled “very carefully and done with consent”.

He said: “Scotland’s life sciences sector has an annual turnover of more than £8 billion and is one of our key sectors for transformative economic growth.

“This partnership will be able to leverage our world-leading universities, life sciences hubs and excellent healthcare systems to support the growth of the sector and development of entrepreneurs.

“Testing products in a real world environment and accelerating development is vital, and will enable a broader reach of the Techscaler programme.

“This, in turn, will benefit patients and medical staff as they develop cutting-edge technology for use across the NHS, from stroke and rehabilitation through to reducing drug-related deaths.

“It is a further example of the steps we are taking as we develop a sustainable, high-skill economy that works for everyone.”

The Government’s chief entrepreneur Mark Logan said: “By making this connection between health testing and business support, we create an environment for innovation which enables Scottish companies to compete effectively whilst bringing much-needed treatment solutions to the NHS.”

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in